-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial
By Mariano Provencio, MD, PhD Posted: June 24, 2020 Data can help inform change to standard of care, but at what point do we say enough data is enough and move forward with combination therapy as the new standard of care? Stage IIIA disease accounts for approximately 15% to 20% of all lung cancers. This…
-
Oncology Trials Could Benefit From Increased Data on Tobacco Use
By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, should be a required data element for all prospective clinical studies and that these studies should consider designs that could also determine the most effective…
-
TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation
By Paul Baas, MD, PhD, and Cornedine J. de Gooijer, MD Posted: June 24, 2020 Recently, a manuscript by Ceresoli et al. was published in The Lancet Oncology.1 The study states that the use of tumortreating fields (TTFields) is a major improvement in the treatment of patients with mesothelioma compared to previous standards.2 Herein, we…
-
Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories
By Ricardo Sales dos Santos, MD, PhD, and Juliana Franceschini, PhD Posted: June 24, 2020 Dr. Juliana Franceschini Dr. Ricardo Sales dos Santos The reality of lung cancer in Brazil is as alarming as it is in the rest of the…
-
Insight Into Genomic Correlates of PD-L1 Expression and the Response to Immune Checkpoint Blockade
By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients most likely to benefit from such therapy. New work carried out by researchers at the Dana-Farber Cancer Institute has identified a handful of genetic variants…
-
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless of EML4-ALK variant type and across a variety of ALK resistance mutations. The duration of response also appears consistent across all ALK fusion subtypes. “Our…
-
Paul G. Kluetz, MD
Posted: June 24, 2020 Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the OCE’s Patient-Focused Drug Development program. The IASLC looks forward to our continued collaboration and partnership with the FDA with regard to lung cancer therapies, diagnostics,…
-
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. As reported at AACR, the trial showed that combined second-line treatment with camrelizumab, a PD-1 inhibitor, and apatinib, a VEGFR2 inhibitor, demonstrated promising antitumor activity…
-
Multidisciplinary Tumor Boards: Approaches Across Different Institutions
Posted: June 24, 2020 In an effort to provide its audience with information about best practices for multidisciplinary communication, ILCN will be highlighting the approaches of different international institutions. From sharing information on who is included in discussions to the results of formalized processes, authors from each institution provide numerous organizational and clinical pearls. Multidisciplinary…
-
Shirish Gadgeel, MD
Posted: June 24, 2020 Shirish Gadgeel, MD, is now the Chief of Division of Hematology and Oncology and Associate Director of Patient Experience and Clinical Care at Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, Michigan. He is also a Professor at Wayne State University, where he previously served as leader of the Thoracic Oncology Multidisciplinary…
View ILCN Archives
Provider Resources
Popular Articles